about
Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal StudiesProdromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons LearnedJC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein levelUric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients.Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015Impulsive-compulsive behaviors in parkin-associated Parkinson disease.Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.Molecular and Metabolic Imaging in Multiple Sclerosis.The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study.Predictors of the 10-year direct costs for treating multiple sclerosis.Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis.Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.White matter changes and the development of motor phenotypes in de novo Parkinson's Disease.The Dress: Transforming a web viral event into a scientific survey.Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy.Uric acid: a potential biomarker of multiple sclerosis and of its disability.A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects.Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale.Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study.Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study.Cardiovascular profile improvement during Natalizumab treatment.Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study.Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease.The Framingham cardiovascular risk score in multiple sclerosis.Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease.Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression.Hearing impairment in Parkinson's disease: expanding the nonmotor phenotype.Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.Diagnostic challenges of Parkinsonism occurring in multiple sclerosis.Ping-pong gaze: Sherrington would not have done it better.Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.A longitudinal real-life comparison study of natalizumab and fingolimod.The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
P50
Q24658443-4F13F4F1-F9BC-4805-9340-F4097575FEC4Q26738357-946952C7-AC71-4BF3-9429-D0DB9DE4FB81Q34351212-6EA73B7C-DCC7-4CCB-8762-05707663E3A5Q34462274-160C24DF-B7A5-4BED-9FB3-63A8F683586AQ34925276-70DE0D52-04E8-4E17-8DC5-E01714EEF4D0Q36240512-7F2B72C5-D7E3-4135-9230-4C1F3615C92FQ37360530-2E3AE277-9C99-460E-BC1C-BD2DE4784AEBQ38616976-48F04C17-E1AC-4F7D-B584-D6483F1B0A2CQ38732913-A5A2FCFE-1292-4CD7-8A38-88163E7EA7F6Q38810555-AAF028ED-6DFC-462F-AFCE-6CB6BD3EB243Q38847064-2E9B5760-6CAA-4121-AF29-4E9430030215Q39095348-768A8B5D-7D67-4710-BAD7-427A4E9BD97CQ40367571-9FE17099-8487-472C-BC94-96044875CA62Q40440543-FE7067D6-CF29-43B4-BBD4-85B4468DD6D3Q40538397-49B89378-A6CF-415A-80D9-3F9E634A1A01Q40648235-28FCB708-72F5-41EC-A244-9CA010815730Q40729961-D0B71EE1-C932-4E6D-8253-7ACF37EB7CA4Q43492543-62B63CCB-2EE4-4F73-93E3-3AD40ED00998Q46835954-173688D3-25D5-4035-8F72-2E98F2ADFC46Q47582506-5933A973-06D5-45B1-A482-C76A452A0CCCQ47685006-C5A3FB06-CE54-44D8-BABC-AFE761D8478EQ47734400-AAEB46C6-8660-4384-9B8E-B7EA09423505Q47813794-AC830D01-158F-4968-AD2F-0DA2F61A11ECQ47868961-2FD53BC3-0CCE-413A-85F0-ED9A128E6D43Q47873288-D38956B3-9912-4BA6-BD20-8477C62AEF7FQ47903984-462CB00B-9867-4AF0-9713-F04E2E6FFC75Q47907093-6B8D5CA7-67B1-421E-A080-39850127A815Q48113820-EAF49437-4C62-4576-A086-69CD34688BAEQ48123750-60C47E65-CCE1-4A92-A985-2C9A8D90E965Q48158470-D4DE8B97-BF7E-46FB-9A25-444084734907Q48195952-6028C706-A19C-441D-B183-20785FCF7F45Q48237142-E6F3E3D6-1B4D-4C18-8EC1-2DBD9D47A791Q48257014-6685CF5B-2E95-4B92-BF45-C4979E921F0CQ48351834-5F3F67FA-9557-44D7-BC95-AB2FE817AFE1Q48443307-94A87C15-51C9-4884-8A2F-0BFF642C0D44Q48488287-B96541B8-479A-4FD3-95AB-21C752CAE4B6Q48542443-53FACF33-5309-4E61-8C1B-FC64EB926221Q48606479-036BFAC5-2967-4D2F-94E7-8734314C29AEQ48650575-CD9175E2-9811-4D57-AE87-322759362F3BQ48748004-7AADAC96-3E0C-49C3-B5D2-4AAC0C238714
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcello Moccia
@ast
Marcello Moccia
@en
Marcello Moccia
@es
Marcello Moccia
@nl
Marcello Moccia
@sl
type
label
Marcello Moccia
@ast
Marcello Moccia
@en
Marcello Moccia
@es
Marcello Moccia
@nl
Marcello Moccia
@sl
altLabel
Moccia M
@en
prefLabel
Marcello Moccia
@ast
Marcello Moccia
@en
Marcello Moccia
@es
Marcello Moccia
@nl
Marcello Moccia
@sl
P1053
N-6987-2015
P106
P1153
36461391900
P21
P2798
P31
P3829
P4012
P496
0000-0003-2613-3090